BenevolentAI Investor Conference Presentation Deck

A clinical-stage Al-enabled drug discovery company SCIENTIFIC VALIDATION 15 3 1 10+ named Platform-generated drug programmes assets in pre-IND asset in Phase II exploratory stage programmes COMMERCIAL VALIDATION 5 novel targets selected for AstraZeneca's portfolio REGULATORY VALIDATION FDA approval of COVID-19 treatment identified by BenevolentAl Benevolent 3

View entire presentation